Chronic myelogenous leukemia

Susan O'Brien, Ellin Berman, Kapil Bhalla, Edward A. Copelan, Marcel P DeVetten, Peter D. Emanuel, Harry P. Erba, Peter L. Greenberg, Joseph O. Moore, Donna Przepiorka, Jerald P. Radich, Russell J. Schilder, Paul Shami, B. Douglas Smith, David S. Snyder, Robert J. Soiffer, Martin S. Tallman, Moshe Talpaz, Meir Wetzler

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2007, an estimated 4500 cases will be diagnosed and 900 patients will die of the disease. The goal of CML therapy is complete remission, which typically progresses from hematologic to cytogenetic remission. These updated 2007 guidelines include changes to several treatment recommendations, including considerations for imatinib dosing, the use of interferon, and management of dasatinib toxicity. Recommendations for hematopoetic stem cell transplantation have also been updated.

Original languageEnglish (US)
Pages (from-to)474-496
Number of pages23
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume5
Issue number5
Publication statusPublished - May 1 2007

    Fingerprint

Keywords

  • Chronic myelogenous leukemia
  • Desatinib
  • Imatinib
  • Karyotyping
  • NCCN clinical practice guidelines
  • Polymerase chain reaction
  • Transplantation

ASJC Scopus subject areas

  • Oncology

Cite this

O'Brien, S., Berman, E., Bhalla, K., Copelan, E. A., DeVetten, M. P., Emanuel, P. D., ... Wetzler, M. (2007). Chronic myelogenous leukemia. JNCCN Journal of the National Comprehensive Cancer Network, 5(5), 474-496.